Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk: How to Analyze, Summarize and Interpret to Determine Risk / Edition 1

Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk: How to Analyze, Summarize and Interpret to Determine Risk / Edition 1

by Michael J. Klepper, Barton Cobert
ISBN-10:
0763769126
ISBN-13:
9780763769123
Pub. Date:
09/29/2010
Publisher:
Jones & Bartlett Learning
ISBN-10:
0763769126
ISBN-13:
9780763769123
Pub. Date:
09/29/2010
Publisher:
Jones & Bartlett Learning
Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk: How to Analyze, Summarize and Interpret to Determine Risk / Edition 1

Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk: How to Analyze, Summarize and Interpret to Determine Risk / Edition 1

by Michael J. Klepper, Barton Cobert

Paperback

$192.95 Current price is , Original price is $192.95. You
$192.95 
  • SHIP THIS ITEM
    Qualifies for Free Shipping
  • PICK UP IN STORE
    Check Availability at Nearby Stores

Overview

Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk was selected for The First Clinical Research Bookshelf - Essential reading for clinical research professionals by the Journal of Clinical Research Best Practices.

Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides drug safety/pharmacovogilance professionals, pharmaceutical and clinical research scientists, statisticians, programmers, medical writers, and technicians with an accessible, practical framework for the analysis, summary and interpretation of drug safety data.

The only guide of its kind, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is an invaluable reference for pre- and post-marketing risk assessment. With decades of pharmaceutical research and drug safety expertise, authors Dr. Klepper and Dr. Cobert discuss how quality planning, safety training, and data standardization result in significant cost, time, and resource savings. Through illustrative, step-by-step instruction, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is the definitive guide to drug safety data analysis and reporting.

Key features include:
* Step-by-step instruction on how to analyze, summarize and interpret safety data for mandatory governmental safety reports
* Pragmatic tips…and mistakes to avoid
* Simple explanations of what safety data are collected, and what the data mean
* Practical approaches to determining a drug effect and understanding its clinical significance
* Guidance for determining risk throughout the lifecycle of a drug, biologic or nutraceutical
* Examples of user-friendly data displays that enhance safety signal identification
* Ways to improve data quality and reduce the time, resources and costs involved in mandatory safety reporting
* Relevant material for the required training of drug safety/pharmacovigilance professionals
* SPECIAL FEATURE: Actual examples of an Integrated Analysis of Safety (IAS) -used in the preparation of the Integrated Summary of Safety (ISS) and the Summary of Clinical Safety (SCS) reports -, and the Periodic Safety Update Report (PSUR)

Product Details

ISBN-13: 9780763769123
Publisher: Jones & Bartlett Learning
Publication date: 09/29/2010
Edition description: 1E
Pages: 316
Product dimensions: 8.40(w) x 10.80(h) x 0.80(d)

About the Author

President, Michael J. Klepper, MD, LLC, Research Triangle Park, North Carolina


President, BLCMD Associates LLC, Westfield, New Jersey

Table of Contents

Part 1 The Basics
Chapter 1 Benefit-Risk
Chapter 2 Begin at the End
Chapter 3 The “Dynamic” Integrated Safety Database - Something You Shouldn’t Live Without
Chapter 4 Coding Basics
Chapter 5 Determining Causality – The Individual Case Safety Report
Chapter 6 Determining Causality – Aggregate Data
Chapter 7 Determining the Weight of Evidence – Patterns and Links
Chapter 8 Determining Clinical Significance…and Then What?
Chapter 9 Clinical Lab oratory Tests - What Is Measured; What It Means
Chapter 10 12-Lead Electrocardiograms - What Is Measured; What It Means
Chapter 11 Adverse Events That Should Be on Everyone's Radar Screen
Part 2 Approaches to the Analysis, Summary, and Interpretation of Safety Data
Chapter 12 Exposure
Chapter 13 Demographics and Other Baseline Characteristics
Chapter 14 Disposition
Chapter 15 Adverse Events Part 1: Common Adverse Events
Chapter 16 Adverse Events Part 2: Deaths, Other Serious Adverse Events, Other Significant Adverse Events, and Analysis of Adverse Events by Organ System or Syndrome
Chapter 17 The Analysis of Lab oratory Data
Chapter 18 The Analysis of Vital Signs, Physical Findings, and Other Observations Related to Safety
Chapter 19 The Analysis of Electrocardiograms
Chapter 20 Safety in Special Groups and Situations – Intrinsic Factors, Extrinsic Factors, and Drug Interactions
Chapter 21 Use in Pregnancy and Lactation
Chapter 22 Overdose
Chapter 23 Drug Abuse
Chapter 24 Withdrawl and Rebound
Chapter 25 Effects on Ability to Drive or Operate Machinery or Impairment of Mental Ability
Appendix 1 Introducing Mepro – A Fictitious Drug
Appendix 2 The Integrated Analysis of Safety for Mepro
Appendix 3 Company Core Safety Information for MEPRO (Meproamine Dihydroacetate)
Appendix 4 6-Month Periodic Safety Update Report - Mepro
Appendix 5 Clinically Significant Criteria for Lab oratory, Vital Signs, Body Weight, Body Mass Index, and Electrocardiogram Parameters
From the B&N Reads Blog

Customer Reviews